Home > Insider Trading > Filing (0001104659-25-051161)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1526119	Verastem Inc.	VSTM	Pharmaceutical Preparations (2834)	273269467

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563202	Dan Paterson	C/O Verastem, Inc., 117 Kendrick St., Suite 500 Needham MA 02494	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2025-05-16	25,000	$0.00	370,659	No	4	A	Direct
Common Stock	Disposition	2025-05-16	150,000	$0.00	520,659	No	4	A	Direct
Common Stock	Disposition	2025-05-20	58,677	$8.13	461,982	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Footnotes

The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on August 2, 2023. 25,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the U.S. Food and Drug Administration (the "FDA") of a new drug application ("NDA") for a product which contains avutometinib in combination with defactinib had occurred.
The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.
The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.